Skip to main content
. Author manuscript; available in PMC: 2012 Jan 1.
Published in final edited form as: Neurobiol Learn Mem. 2010 Nov 17;95(1):73–79. doi: 10.1016/j.nlm.2010.11.009

Fig. 2.

Fig. 2

CDPPB does not influence spontaneous locomotor activity but attenuates MK-801-induced hyperlocomotion. (A) Animals were injected s.c. with Vehicle (0), 3 or 10 mg/kg CDPPB 20 minutes before being placed in the activity chamber. (B) Animals were injected (s.c./i.p.) with PBS/Vehicle (0/0), 0.2 mg/kg MK-801/Vehicle (0.2/0), 0.2 mg/kg MK-801/3 mg/kg CDPPB (0.2/3) or 0.2 mg/kg MK-801/10 mg/kg CDPPB (0.2/10) 20 minutes before being placed in the activity chamber. Activity was recorded for 30 minutes. Data are expressed as mean ± SEM of distance traveled (n=6-7). **p<0.01 vs. 0.2 mg/kg MK-801/Vehicle group (One-way ANOVA, Bonferroni’s posttest).